Aurobindo Pharma, a leading drug manufacturer, has announced that it has got tentative sanction from the US Food and Drug Administration (USFDA) for PerindopriL Erbumine tablets.

The approval has been granted for 2 mg, 4 mg and 8 mg dosage of drug.

According to the sources, PerindopriL Erbumine tablets are indicated for the treatment of high blood pressure.  
 
The sources further revealed that the conglomerate has also received tentative approval for Escitalopram Oxalat Oral solution 5 mg base/5 ml.  

Escitalopram Oxalate Oral solution is indicated for the treatment of major depressive disorder and other related problems. The drug is an active isomer of the antidepressant drug Celexa.
 
Scrip of Aurobindo Pharma has finally settled into green with a gain of 7.95 percent at Rs 116 on National Stock Exchange (NSE). The total volume of shares traded at NSE was 260,256.